429 related articles for article (PubMed ID: 30268633)
21. [What attitude to women at high risk of breast cancer?].
Livon D; Moretta J; Noguès C
Presse Med; 2019 Oct; 48(10):1092-1100. PubMed ID: 31706893
[TBL] [Abstract][Full Text] [Related]
22. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G
J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844
[TBL] [Abstract][Full Text] [Related]
23. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
[TBL] [Abstract][Full Text] [Related]
24. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
Sung PL; Wen KC; Chen YJ; Chao TC; Tsai YF; Tseng LM; Qiu JT; Chao KC; Wu HH; Chuang CM; Wang PH; Huang CF
PLoS One; 2017; 12(9):e0185615. PubMed ID: 28961279
[TBL] [Abstract][Full Text] [Related]
25. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
26. Retesting of women who are negative for a
Lerner-Ellis J; Sopik V; Wong A; Lázaro C; Narod SA; Charames GS
J Med Genet; 2020 Jun; 57(6):380-384. PubMed ID: 31784482
[TBL] [Abstract][Full Text] [Related]
27. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
Kleibl Z; Kristensen VN
Breast; 2016 Aug; 28():136-44. PubMed ID: 27318168
[TBL] [Abstract][Full Text] [Related]
28. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
[TBL] [Abstract][Full Text] [Related]
29. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls.
Lilyquist J; LaDuca H; Polley E; Davis BT; Shimelis H; Hu C; Hart SN; Dolinsky JS; Couch FJ; Goldgar DE
Gynecol Oncol; 2017 Nov; 147(2):375-380. PubMed ID: 28888541
[TBL] [Abstract][Full Text] [Related]
30. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
[TBL] [Abstract][Full Text] [Related]
31. The use of panel testing in familial breast and ovarian cancer.
Prapa M; Solomons J; Tischkowitz M
Clin Med (Lond); 2017 Dec; 17(6):568-572. PubMed ID: 29196360
[TBL] [Abstract][Full Text] [Related]
32. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
33. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract][Full Text] [Related]
34. Genetic characterization of early onset ovarian carcinoma.
Bernards SS; Norquist BM; Harrell MI; Agnew KJ; Lee MK; Walsh T; Swisher EM
Gynecol Oncol; 2016 Feb; 140(2):221-5. PubMed ID: 26718727
[TBL] [Abstract][Full Text] [Related]
35. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
Malander S; Rambech E; Kristoffersson U; Halvarsson B; Ridderheim M; Borg A; Nilbert M
Gynecol Oncol; 2006 May; 101(2):238-43. PubMed ID: 16360201
[TBL] [Abstract][Full Text] [Related]
36. Germline mutations in Chinese ovarian cancer with or without breast cancer.
Kwong A; Ho CYS; Shin VY; Au CH; Luk WP; Fung LH; Chan TL; Chan KKL; Ngan HYS; Ma ESK
Mol Genet Genomic Med; 2022 Jul; 10(7):e1940. PubMed ID: 35608067
[TBL] [Abstract][Full Text] [Related]
37. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.
Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM
Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366
[TBL] [Abstract][Full Text] [Related]
39. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.
Kurian AW; Hughes E; Handorf EA; Gutin A; Allen B; Hartman AR; Hall MJ
JCO Precis Oncol; 2017 Nov; 1():1-12. PubMed ID: 35172496
[TBL] [Abstract][Full Text] [Related]
40. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.
Bunnell AE; Garby CA; Pearson EJ; Walker SA; Panos LE; Blum JL
J Genet Couns; 2017 Feb; 26(1):105-112. PubMed ID: 27276934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
